Clinical Trial: Efficacy and Safety of Zorifertinib Combined with Double-Dose Furmonertinib and Pemetrexed Intrathecal Chemotherapy in Treating EGFR-Mutant Non-Small Cell Lung Cancer with Leptomeningeal Metastasis: A Single-Arm, Prospective Clinical Study (China)

China, Sept. 1 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of Zorifertinib Combined with Double-Dose Furmonertinib and Pemetrexed Intrathecal Chemotherapy in Treating EGFR-Mutant Non-Small Cell Lung Cancer with Leptomeningeal Metastasis: A Single-Arm, Prospective Clinical Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131219

Registration Time: 2026/08/31

Type: Interventional study

Primary Sponsor: Nanjing Drum Tower Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=338985

Published by HT Digital Content Services with permission from Health Daily Digest....